RT Journal Article
SR Electronic
T1 Clinical Applications of <sup>18</sup>F-FDG in Oncology
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 3
OP 9
VO 30
IS 1
A1 Hani A. Nabi
A1 José M. Zubeldia
YR 2002
UL http://tech.snmjournals.org/content/30/1/3.abstract
AB PET has emerged as a powerful diagnostic tool for the evaluation of cancer patients. Currently, most of these studies are performed with the glucose analog 18F-FDG, which has been shown to accumulate avidly in most tumors. 18F-FDG PET is now routinely used in the diagnosis, staging, and posttherapy evaluation of oncologic patients. After reading this paper, the reader should understand the physiologic basis of using 18F-FDG in patients with different tumors, describe the role of this radiopharmaceutical in the management of oncologic patients, and identify those malignancies for which 18F-FDG has proved to be effective in diagnosis and follow-up.